These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 3258341)

  • 1. A modified competitive inhibition radioimmunoassay for the detection of C3a. Use of 125I-C3 instead of 125I-C3a.
    Hack CE; Paardekooper J; Eerenberg AJ; Navis GO; Nijsten MW; Thijs LG; Nuijens JH
    J Immunol Methods; 1988 Apr; 108(1-2):77-84. PubMed ID: 3258341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitation of the anaphylatoxin C3a in the presence of C3 by a novel sandwich ELISA using monoclonal antibody to a C3a neoepitope.
    Zilow G; Naser W; Rutz R; Burger R
    J Immunol Methods; 1989 Jul; 121(2):261-8. PubMed ID: 2503562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A simplified assay for the detection of C3a in human plasma employing a monoclonal antibody raised against denatured C3.
    Nilsson B; Svensson KE; Inganäs M; Nilsson UR
    J Immunol Methods; 1988 Mar; 107(2):281-7. PubMed ID: 3257998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of native human complement components C3 and C5 and their primary activation peptides C3a and C5a (anaphylatoxic peptides) by ELISAs with monoclonal antibodies.
    Klos A; Ihrig V; Messner M; Grabbe J; Bitter-Suermann D
    J Immunol Methods; 1988 Jul; 111(2):241-52. PubMed ID: 3260926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a simple radioimmunoassay for human C3a.
    Lamche HR; Paul E; Schlag G; Redl H; Hammerschmidt DE
    Inflammation; 1988 Jun; 12(3):265-76. PubMed ID: 3262087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitation of C3a by ELISA using a monoclonal antibody to a neoantigenic C3a determinant.
    Zilow G; Naser W; Friedlein A; Bader A; Burger R
    Prog Clin Biol Res; 1989; 308():299-304. PubMed ID: 2476822
    [No Abstract]   [Full Text] [Related]  

  • 7. Functional analysis and quantification of the complement C3 derived anaphylatoxin C3a with a monoclonal antibody.
    Burger R; Bader A; Kirschfink M; Rother U; Schrod L; Wörner I; Zilow G
    Clin Exp Immunol; 1987 Jun; 68(3):703-11. PubMed ID: 3498585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Demonstration in human plasma of a form of C3 that has the conformation of "C3b-like C3".
    Hack CE; Paardekooper J; Van Milligen F
    J Immunol; 1990 Jun; 144(11):4249-55. PubMed ID: 1692860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leukocyte aggregation response to quantitative plasma levels of C3a and C5a.
    Williams JJ; Yellin SA; Slotman GJ
    Arch Surg; 1986 Mar; 121(3):305-7. PubMed ID: 3484946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Formation of C3-IgG complexes in serum by aggregated IgG and by non-immunoglobulin activators of complement.
    van Dam AP; Hack CE
    Immunology; 1987 Jun; 61(2):105-10. PubMed ID: 3596635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Complement activation in patients with chronic polyarthritis, measured by the level of complement fraction C3a in plasma].
    Kapp A; Meske-Brand S; Maly FE; Müller W
    Z Rheumatol; 1984; 43(3):103-5. PubMed ID: 6332437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C3, C5 components and C3a, C4a, and C5a fragments of the complement system.
    Janatova J
    Methods Enzymol; 1988; 162():579-625. PubMed ID: 3265757
    [No Abstract]   [Full Text] [Related]  

  • 13. The C terminus of the anaphylatoxin C3a generated upon complement activation represents a neoantigenic determinant with diagnostic potential.
    Burger R; Zilow G; Bader A; Friedlein A; Naser W
    J Immunol; 1988 Jul; 141(2):553-8. PubMed ID: 2454995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ELISA of complement C3a in bronchoalveolar lavage fluid.
    van de Graaf EA; Jansen HM; Bakker MM; Alberts C; Eeftinck Schattenkerk JK; Out TA
    J Immunol Methods; 1992 Mar; 147(2):241-50. PubMed ID: 1548406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement activation during cardiopulmonary bypass in children.
    Meri S; Aronen M; Leijala M
    Complement; 1988; 5(1):46-54. PubMed ID: 2962816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A screening test for modified hemoglobin blood substitutes before clinical use: based on C3a complement activation in human plasma.
    Chang TM; Lister C
    Biomater Artif Cells Artif Organs; 1990; 18(5):693-701. PubMed ID: 2099226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of plasma C3a des Arg levels after blood contact with foreign surfaces.
    Spencer PC; Schmidt B; Gurland HJ
    Artif Organs; 1986 Feb; 10(1):61-3. PubMed ID: 3964100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantification in enzyme-linked immunosorbent assay of a C3 neoepitope expressed on activated human complement factor C3.
    Garred P; Mollnes TE; Lea T
    Scand J Immunol; 1988 Mar; 27(3):329-35. PubMed ID: 2451274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of complement activation during cardiopulmonary bypass. Attenuation by hypothermia, heparin, and hemodilution.
    Moore FD; Warner KG; Assousa S; Valeri CR; Khuri SF
    Ann Surg; 1988 Jul; 208(1):95-103. PubMed ID: 3260474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complement activation during systemic lupus erythematosus. C3a and C5a anaphylatoxins circulate during exacerbations of disease.
    Belmont HM; Hopkins P; Edelson HS; Kaplan HB; Ludewig R; Weissmann G; Abramson S
    Arthritis Rheum; 1986 Sep; 29(9):1085-9. PubMed ID: 3489467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.